Trials / Completed
CompletedNCT05362045
A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
Bioequivalence Study of a Single Dose of 15-mg Mavacamten Capsule Versus a Single Dose of 3 x 5-mg Mavacamten Capsules in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 158 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effects on the single-dose drug levels of mavacamten in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mavacamten | Specified dose on specified days |
Timeline
- Start date
- 2022-05-16
- Primary completion
- 2022-08-19
- Completion
- 2022-08-19
- First posted
- 2022-05-05
- Last updated
- 2022-11-21
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05362045. Inclusion in this directory is not an endorsement.